AUTHORS
Ayodeji David Johnson, MD, Tornike Zabakhidze, MD2, Courage Idahor, MD3, Emmanuel Nsa Ekpenyong, MD4, Oladayo A Oyebanji, MD, MS5, Chinenye Egwuonwu, MD, MPH6, Jude Odinakachukwu Ossai, MD7, Larry Chin, MD8
AFFILIATIONS
1 Boston medical Center, Boston, United States
2 BOSTON MEDICAL CENTER, Boston, United States
3 Henry Ford providence, Southfield, United States
4 Mobile infirmary medical center, Mobile, United States
5 case western reserve, cleveland, United States
6 Piedmont Athens regional medical center, Athens, United States
7 Newark Beth Israel, newark, United States
8 BOSTON MEDICAL CENTER, Boston, United States
ABSTRACT
Background: The ECHELON-2 trial established brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) as a standard frontline regimen for CD30-positive peripheral T-cell lymphoma (PTCL), improving progression-free and overall survival versus CHOP. However, real-world data on comparative toxicity and mortality outcomes outside the trial setting remain limited. We used a large federated real-world database to compare survival and treatment-related morbidity between BV-CHP and CHOP in routine clinical practice.
Methods: Using the TriNetX Global Collaborative Network (179 healthcare organizations), we identified adults with CD30-associated PTCL subtypes (including ALCL and PTCL-NOS) who received BV-CHP (n=320) or CHOP (n=392) on or after Nov 11, 2018. The index event was the first qualifying chemotherapy administration. Cohorts were 1:1 propensity-score matched (n=273 per arm) on age, sex, and comorbidity burden (hypertension, CKD, heart failure), achieving standardized differences <0.1 for all covariates. Outcomes over a 5-year window included all-cause mortality, sepsis, pneumonia, drug-induced polyneuropathy, transfusion requirement, anemia, and thrombocytopenia, assessed using risk ratios, Kaplan-Meier estimates, and Cox proportional hazards models.
Results: After matching, BV-CHP was associated with significantly lower 5-year mortality (33.7% vs. 44.7%; risk ratio [RR] 0.75, 95% CI 0.61–0.93; HR 0.67, 95% CI 0.51–0.88; p=0.004) compared with CHOP. BV-CHP was also associated with significantly lower rates of sepsis (19.0% vs. 28.9%; HR 0.57, p=0.001), transfusion (24.2% vs. 32.2%; HR 0.63, p=0.005), and thrombocytopenia (22.3% vs. 32.2%; HR 0.57, p=0.001), and lower Kaplan-Meier-estimated anemia despite a non-significant risk-ratio comparison (33.3% vs. 39.9%; HR 0.71, p=0.013). Pneumonia rates were numerically lower but not statistically different (16.5% vs. 20.5%; p=0.23). Conversely, drug-induced polyneuropathy was significantly more common with BV-CHP (14.3% vs. 8.1%; RR 1.77, 95% CI 1.08–2.91; p=0.021), consistent with the known neurotoxicity profile of brentuximab vedotin.
Conclusions: In this large propensity score-matched real-world study, frontline BV-CHP was associated with improved overall survival and lower rates of serious treatment-related complications compared with CHOP in patients with CD30-positive PTCL. These findings support the real-world effectiveness of BV-CHP and reinforce its role as the preferred frontline regimen for eligible patients, while emphasizing the need for proactive monitoring of treatment-related peripheral neuropathy. Future studies should evaluate which patient subgroups derive the greatest benefit from BV-CHP and identify strategies to minimize toxicity without compromising efficacy.
DISCLOSURES
Ayodeji David Johnson, MD: No relevant conflicts of interest to declare.